There are two major neoplasms in chickens, and each is induced by a different class of viruses. One of these, Marek's disease (MD), is characterized by high mortality of chickens, with tumors of the viscera at less than 8 weeks of age, and became a problem in the United States in the 1950's (9) . After intense study a herpesvirus termed Marek's disease virus (MDV) was associated with the tumors and shown to be the etiologic agent (4, 10, 40) . MDV isolates were categorized into three classes based on serological characteristics. The pathogenic strains (serotype 1), nononcogenic MDVs from chickens (serotype 2), and the related nononcogenic turkey herpesvirus (HVT) (serotype 3) (46) were all serologically distinct (41) . Monoclonal antibodies have been developed that distinguish between the three types (23) . Shortly after MD herpesviruses were isolated, some serotype 1 attenuated (11) and serotype 3 (28) viruses were developed as successfull cell-associated vaccines against MD; these were the first successful vaccines used worldwide to combat tumors in any species (9) . Later, when more virulent forms of MDV were described (48) , the serotype 2 viruses were also developed and used, mainly as bivalent vaccines (7, 42) .
The second major neoplasm in chickens is termed lymphoid leukosis (LL) (32) . Retroviruses termed avian leukosis viruses (ALV), which also serve as helper viruses to defective Rous sarcoma viruses (33, 34) , were shown to determine LL (3) as well as other forms of leukosis (3, 32) . LL was a major cause of mortality to the poultry industry, causing B-cell lymphomas in chickens generally over 5 months of age (32) .
Some studies have questioned the ability of ALV to cause LL or MDV to cause MD or have concluded there is an * Corresponding author.
interaction between the two (20, 22, 29) . Other studies with chickens confined in specific-pathogen-free isolators and infected with purified virus have definitely established an independent oncogenic potential for ALV and MDV (6, 45) . However, the latter and subsequent vaccine studies have not included groups infected with controlled levels of different ALVs and different classes of MD viruses to assess whether one may augment tumors initiated by the other. Moreover, in one field test of bivalent MD vaccines two of five commercial strains vaccinated with or contact exposed to the bivalent vaccine developed a high level of LL mortality (47) . This and other field and laboratory observations led us to test whether MD herpesviruses could augment LL development.
In this study, chickens vaccinated with different serotypes of MD virus and inoculated with exogenous ALV were studied for the duration of ALV viremia, the development of neutralizing antibodies to ALV, and the onset of LL development. An augmentation of LL was seen in chickens of two strains receiving one bivalent vaccine. Therefore, additional experiments were conducted by using that vaccination procedure on chickens of several different strains. Also, chickens in one LL-augmentable strain were vaccinated with combinations of several additional isolates of the three MDV serotypes, and some were exposed to MDV or ALV by infection from hatchmates. Chickens from these lines were progeny of parents determined to be free of exposure to ALV, MDV (serotypes 1 and 2), and other pathogens by periodical serologic monitoring (14) . Commercial chickens were hatched from fertile eggs provided by several breeders. One strain of feathersexed White Leghorn (WL) chickens (designated A) in which LL was previously observed after bivalent vaccination (47) was used in experiments 2 and 3. Chickens from another feather-sexed WL strain (D), two rapid-feathering WL strains (B and C), and a female broiler breeder strain (E) were also used in experiment 3. All of the chickens (except line 63) were produced by hens vaccinated with HVT.
Viruses. Chickens were injected with 103 infectious units of ALV strain RPL-42 (18) (kindly supplied by L. B. Crittenden) into the jugular vein (experiments 1 and 2) or peritoneal cavity (experiment 3). RPL-42 is an uncloned field isolate containing only subgroup A virus that has been passed several times on C/E cells and is known to produce a variety of neoplasms depending on the dose of the virus, age at exposure or inoculation, and strain of chicken (17, 19) . Some chickens in experiment 3 were infected by contact exposure at hatch to 1-day-old 1515 x 71 shedder chickens that had been inoculated in the yolk sac as 7-day embryos with RPL-42 (12, 19) . Cloacal swabs and plasma samples for virus and antibody tests were collected (12) and stored in a nitrogen vapor storage tank. Several assays were used to detect exogenous ALV. Briefly, C/E chicken embryo fibroblasts (resistant to endogenous viruses) were infected with samples as described by Crittenden et al. (12) . Plates were frozen and thawed, and samples were collected from the supernatant after 9 days of culture and assayed for the presence of ALV group-specific antigen by using the enzyme-linked immunosorbent assay of Smith et al. (39) . Each culture supernatant was run in duplicate, and cultures were considered ALV positive if both supernatants had absorbance readings more than 0.2 units above the readings of control supernatants, which were cultures inoculated with material containing no exogenous ALV and tested on the same enzyme-linked immunosorbent assay plate. Neutralization tests for antibody to subgroup A ALV were conducted by incubating 0.1 ml of a 1:5 dilution of heatinactivated plasma with an equal amount of appropriately diluted Rous sarcoma virus before infection of chicken embryo fibroblasts (31) . A 90% or greater reduction in focus-forming units in this assay indicates the presence of antibody to ALV.
In most experiments, the chickens were protected against MD by immunization at 1 day of age with a total of 2,000 PFU of the FC126 strain of HVT (46) , a serotype 2 isolate, SB1 (35) , or a mixture containing equal portions of HVT and SB1, grown in chicken embryo fibroblasts, and used as a cell-associated preparation. Additional MD herpesviruses used in one experiment included serotype 3 virus AC16 (46), a serotype 2 virus 301/B (43), attenuated serotype 1 viruses CV1988/C (16) and Mdll/75C/R2 (R2) (44) , and the virulent serotype 1 viruses JM102W (37) and GA-22 (30) . The vaccine lots used were free of exogenous ALV based on the tests described above.
Pathology. All birds that died and all survivors of the ALV challenge were necropsied. Tissues were examined histologically where macroscopic evidence of tumors was uncertain.
Statistical analysis. Tumor incidence, antibody, and virus percentage data were analyzed by the chi-square method. Median survival times for groups were estimated by the nomographic method of Litchfield (24) . LL tumors at the termination of the study, whereas 50% of those receiving HVT had LL (P < 0.05). In females receiving HVT there was a significant difference in LL tumor development between the 15.6-2 and 15.P-13 B congenic lines (37 and 61%, respectively, with LL; P < 0.05). Resistant 63 males and females did not develop LL tumors after HVT-SB1 vaccination.
RESULTS

Augmentation
The ability of strain RPL-42 to produce viremia and the ability of the chickens to develop neutralizing antibodies are presented in Table 2 . At 16 and 22 weeks, virus was detected in cloacal swabs or plasma samples of essentially all birds. There was no consistent difference within line in the frequency of birds with ALV antibody between groups vaccinated with HVT and HVT-SB1. Virus isolations were done on a subsample of chickens to verify that the HVT vaccinees were not inadvertently exposed to serotype 2 (SB1) MDV (see footnotes to Table 4 for methods). Serotype 2 MDV was undetected in HVT vaccinees but was present in one of four HVT-SB1 vaccinees.
(ii) Experiment 2. Chickens of the susceptible 15.B2 B congenic lines and of ALV-susceptible commercial WL strain A were selected to confirm experiment 1. The commercial-strain females and chickens of both sexes in the 15.B2 line were observed for LL through 48 weeks of age (Table 3 and Fig. 1 ). The results of two hatches were similar, and the data were pooled for analysis. In the 15.B2 chickens inoculated with RPL-42, the HVT-vaccinated and nonvaccinated groups did not differ in final LL loss (56 and 70%, respectively), whereas 98% of the HVT-SB1 vaccinees had LL (P < 0.05). At earlier ages, the group differences were even more dramatic (Fig. 1) , and this was verified in computation of the median survival time. The chickens vaccinated with HVT-SB1 had a median survival time before LL of 155 days, in contrast to 230 or 290 days in unvaccinated or HVT-vaccinated 15.B2 chickens. The commercial-strain females inoculated with RPL-42 and vaccinated with HVT also did not differ in LL development from RPL-42-exposed unvaccinated controls (59 and 48%, respectively), whereas 84% of the HVT-SB1 vaccinees had LL (P < 0.05). Again, the differences were greatest at earlier ages ( Fig. 1) , and the MST before LL in the HVT-SB1 vaccinees was 165 days in contrast to 290 or 330 days in HVT-vaccinated and unvaccinated commercial strain A females. An unvaccinated control lot of commercial strain A that received no RPL-42 had 17% LL; this was attributed to uncontrolled maternal transmission of ALV, which occasionally occurs in this strain.
Tests to confirm the presence of herpesviruses and exogenous ALVs in experiment 2 are summarized in Table 3 .
chickens developed less LL than did HVT-SB1 vaccinees (30 versus 72%; P < 0.05).
In the WL strains B, C, and D, there was no significant difference on LL development between the HVT-vaccinated lot and the HVT-SB1-vaccinated lot. These lots had from 6 to 22% LL, although kept to 34 weeks. About half of the broiler birds had nonspecific mortality, but none developed LL. The experimental (1515 x 71)Fl susceptible control line differed in LL response depending on the use of HVT or HVT-SB1 vaccine (81 versus 100%; P < 0.05), and prominent differences in the median survival time before LL were noted (124 versus 199 days; P < 0.05).
Relationship of MD herpesvirus serotype to the augmentation of retrovirus-induced LL. The previous experiments indicated that an MD vaccine containing SB1 in combination with HVT augmented the development of LL in susceptible strains in contrast to HVT vaccination. Therefore we screened the ability of several serotype 3-, 2-, and 1-virulent or 1-attenuated vaccines alone or in mixtures to augment tumors in the susceptible commercial WL strain A (Table 6 ).
This work was done concurrently with that in Table 5 , and therefore some control lots are identical. Of Several additional lots were studied to determine whether the method of presentation or quantity of SB1 would influence the augmentation of LL tumors (Table 7) . One lot of hatched RPL-42-infected chickens grown with chickens shedding SB1 had a higher percentage of LL than did chickens of another lot where the SB1 was injected (91 versus 50% LL; P < 0.05). The chickens exposed by contact also had a shorter survival time. In two other bivalent vaccine lots, both receiving 1,000 PFU of FC126, the LLaugmenting ability of 100 and 1,000 PFU of inoculated SB1 was compared. Both lots had 76% LL, indicating that only small amounts of SB1 are needed to augment LL. The one receiving only 100 PFU had a shorter median survival time (156 versus 172 days; P < 0.05).
Pathology. Characteristics of LL lymphomas from chick- (36) . It is possible that the hyperplasia in B cells after vaccination or infection with the serotype 2 MDV differs from that resulting from HVT and results in a higher frequency of transformation in the B cells of retrovirus-infected birds. Calnek et al. (8) have shown that viral internal antigens that are an indication of herpesvirus genome turn-on are expressed in cultured spleen cells much more frequently and in higher numbers when the cells are from SB1-infected as opposed to HVT-infected chickens. They also present indirect evidence that B cells are infected with SB1 in contrast to HVT, and they conclude that latent infections with HVT differ qualitatively as well as quantitatively from those with SB1.
In conclusion, we have demonstrated that ALV-induced LL is augmented by serotype 2 MD herpesvirus given alone or in concert with serotype 3-or 1-attenuated vaccine MDVs in LL-susceptible strains of chickens. The mechanism(s) determining this phenomenon may involve B-cell hyperplasia and could be comparable to one of those operating to determine similar herpesvirus-retrovirus augmentation syndromes in humans (15, 25, 26) .
